Mindfulness
February 1, 2020
Alice E. Buxton, Carina Remmers, Hans-Peter Unger et al.
Abstract Objectives Recent preliminary evidence suggests that mindfulness-based programmes may be beneficial in the treatment of patients suffering from current depression. Due to the heterogeneity of patients with this diagnosis, a specialisation in treatment concepts for subgroups of patients may be beneficial. Methods This randomised controlled pilot study investigated the effectiveness of...
Psychiatric Annals
February 1, 2020
Hatice Guncu Kurt, Murat Altinay, Amit Anand
Patients who have not responded to two antidepressant trials in their current depressive episode are usually considered to have treatment-resistant depression (TRD). A detailed search on PubMed was conducted for reported response and remission rates for non-ketamine and ketamine treatments for TRD. From a variety of pharmacological and brain stimulation open-label studies, the treatments were...
Psychiatric Annals
February 1, 2020
Lynnette A. Averill, Christopher L. Averill, Chadi G. Abdallah
6 citations
The serendipitous discovery of ketamine's robust antidepressant effects has served as a major catalyst to usher in new era of drug development and a paradigm shift in our understanding of the neurobiology of chronic stress pathology (CSP). This review provides a selective synthesis of (1) the historical foundations of N-methyl-D-aspartate receptor modulators and the path to discovering...
Current Topics in Medicinal Chemistry
January 31, 2020
Domenico de Berardis, Carmine Tomasetti, Maurizio Pompili et al.
38 citations
BACKGROUND: A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an...
Electronic Physician
January 22, 2020
Mostafa Haghshenas, Fatemeh Assarian, Abdollah Omidi et al.
Background: Diseases with a chronic and debilitating nature, such as chronic kidney disease, are frequently associated with psychiatric disorders like anxiety and depression. Objective: To assess the efficacy of mindfulness-based stress reduction (MBSR) on anxiety and depression in hemodialysis patients. Methods: In this randomized clinical trial, fifty hemodialysis patients were selected from...
BMC Neurology
January 21, 2020
J. Hearn, A. Cross
Background Populations with reduced sensory and motor function, such as spinal cord injury (SCI) are at increased risk of depression, anxiety, pain, and poorer quality of life (QoL). Mindfulness-Based Interventions (MBIs) have been developed with the aim of improving outcomes for people with SCI. To understand the value of MBIs, a systematic review was conducted pertaining to the use of MBIs,...
Ukraïnsʹkij žurnal medicini bìologìï ta sportu
January 17, 2020
A. Kyselova, Chodakowska Warsaw Poland, E. Kravtsova et al.
Depression is one of the most common diagnoses which patients with mood disorders can hear every day. It is a serious condition which influences both physical and mental health. There are several causes of depression (for instance, abuse, certain medications, conflicts at home, work, school, university, etc). Basically, symptoms can vary from feelings of unhappiness and hopelessness to losing...
Journal of Psychopharmacology
January 16, 2020
Lea J. Mertens, Matthew B. Wall, Leor Roseman et al.
211 citations
Background: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed actions of antidepressants, we recently found increased amygdala responsiveness to fearful faces one day after open-label treatment with psilocybin (25 mg) in 19 patients with treatment-resistant depression, which correlated with...
Trials
January 8, 2020
Abhimanyu Sud, M. Nelson, Darren K. Cheng et al.
Background Despite the high prevalence of comorbid chronic pain and depression, this comorbidity remains understudied. Meditation has demonstrated efficacy for both chronic pain and depression independently, yet there have been few studies examining its effectiveness when both conditions are present concurrently. Furthermore, while meditation is generally accepted as a safe and effective health...
Trials
January 6, 2020
Artjom Frick, Isabel Thinnes, Ulrich Stangier
Depression is a widespread disorder with severe impacts for individuals and society, especially in its chronic form. Current treatment approaches for persistent depression have focused primarily on reducing negative affect and have paid little attention to promoting positive affect. Previous studies have shown that metta meditation increases positive affect in chronically depressed patients....